Working… Menu

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04347226
Recruitment Status : Recruiting
First Posted : April 15, 2020
Last Update Posted : October 8, 2020
Bristol-Myers Squibb
Information provided by (Responsible Party):
Matthew Dallos, Columbia University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2022